Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800074 | 0.79 | ICMT (0.35) | CAPN1KMT2A | |
| SCHEMBL22799633 | 0.79 | LIG1 (0.44) | USP2RAB9AKMT2A | |
| SCHEMBL22800161 | 0.78 | CYP3A4 (0.38) | USP2MAPK1NPC1RAB9A | |
| SCHEMBL22800306 | 0.75 | CTSS (0.39) | PTGER4PTGDRCAPN1USP2MAPK1 | |
| SCHEMBL22800155 | 0.75 | MAPT (0.38) | PTGER4PTGDRKMT2A | |
| SCHEMBL22800150 | 0.72 | KDM4E (0.42) | KMT2A | |
| SCHEMBL22800170 | 0.71 | KDM4E (0.43) | KMT2A | |
| SCHEMBL22800154 | 0.71 | ALDH1A1 (0.46) | KMT2A | |
| SCHEMBL22799765 | 0.70 | MAPT (0.35) | — | |
| SCHEMBL20028240 | 0.70 | DCAF1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | PTGER4 3085/4885PTGDR 2439/4885CAPN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.